Combination therapies for multiple sclerosis: Scientific rationale, clinical trials, and clinical practice

Fiona Costello, Olaf Stuve, Martin S. Weber, Scott S. Zamvil, Elliot Frohman

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis. RECENT FINDINGS: Experiments conducted in experimental autoimmune encephalomyelitis have recently shown beneficial effects of numerous combination therapies. The combination of approved and experimental drugs and two or more experimental agents may positively impact clinical disease activity, inflammation within the central nervous system, and neurorepair. Clinical trials are currently underway to establish the therapeutic efficacy and safety of various combination therapies for multiple sclerosis patients. SUMMARY: More effective therapies are needed to treat multiple sclerosis. There are good scientific rationales for the use of combination therapy in multiple sclerosis, and the pharmacologic principles for evaluating and understanding their actions are available. The evaluation of specific combination therapies in the controlled setting of clinical trials should be a priority in clinical multiple sclerosis research.

Original languageEnglish (US)
Pages (from-to)281-285
Number of pages5
JournalCurrent Opinion in Neurology
Volume20
Issue number3
DOIs
StatePublished - Jun 2007

Fingerprint

Multiple Sclerosis
Clinical Trials
Therapeutics
Autoimmune Experimental Encephalomyelitis
Controlled Clinical Trials
Central Nervous System
Animal Models
Inflammation
Safety
Research
Pharmaceutical Preparations

Keywords

  • Combination therapy
  • Experimental autoimmune encephalomyelitis
  • Immunomodulation
  • Immunosuppression
  • Multiple sclerosis
  • Therapy

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Combination therapies for multiple sclerosis : Scientific rationale, clinical trials, and clinical practice. / Costello, Fiona; Stuve, Olaf; Weber, Martin S.; Zamvil, Scott S.; Frohman, Elliot.

In: Current Opinion in Neurology, Vol. 20, No. 3, 06.2007, p. 281-285.

Research output: Contribution to journalArticle

@article{7d75931cfc6b4a5b9a3d35bed24dfb29,
title = "Combination therapies for multiple sclerosis: Scientific rationale, clinical trials, and clinical practice",
abstract = "PURPOSE OF REVIEW: To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis. RECENT FINDINGS: Experiments conducted in experimental autoimmune encephalomyelitis have recently shown beneficial effects of numerous combination therapies. The combination of approved and experimental drugs and two or more experimental agents may positively impact clinical disease activity, inflammation within the central nervous system, and neurorepair. Clinical trials are currently underway to establish the therapeutic efficacy and safety of various combination therapies for multiple sclerosis patients. SUMMARY: More effective therapies are needed to treat multiple sclerosis. There are good scientific rationales for the use of combination therapy in multiple sclerosis, and the pharmacologic principles for evaluating and understanding their actions are available. The evaluation of specific combination therapies in the controlled setting of clinical trials should be a priority in clinical multiple sclerosis research.",
keywords = "Combination therapy, Experimental autoimmune encephalomyelitis, Immunomodulation, Immunosuppression, Multiple sclerosis, Therapy",
author = "Fiona Costello and Olaf Stuve and Weber, {Martin S.} and Zamvil, {Scott S.} and Elliot Frohman",
year = "2007",
month = "6",
doi = "10.1097/WCO.0b013e328122de1b",
language = "English (US)",
volume = "20",
pages = "281--285",
journal = "Current Opinion in Neurology",
issn = "1350-7540",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Combination therapies for multiple sclerosis

T2 - Scientific rationale, clinical trials, and clinical practice

AU - Costello, Fiona

AU - Stuve, Olaf

AU - Weber, Martin S.

AU - Zamvil, Scott S.

AU - Frohman, Elliot

PY - 2007/6

Y1 - 2007/6

N2 - PURPOSE OF REVIEW: To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis. RECENT FINDINGS: Experiments conducted in experimental autoimmune encephalomyelitis have recently shown beneficial effects of numerous combination therapies. The combination of approved and experimental drugs and two or more experimental agents may positively impact clinical disease activity, inflammation within the central nervous system, and neurorepair. Clinical trials are currently underway to establish the therapeutic efficacy and safety of various combination therapies for multiple sclerosis patients. SUMMARY: More effective therapies are needed to treat multiple sclerosis. There are good scientific rationales for the use of combination therapy in multiple sclerosis, and the pharmacologic principles for evaluating and understanding their actions are available. The evaluation of specific combination therapies in the controlled setting of clinical trials should be a priority in clinical multiple sclerosis research.

AB - PURPOSE OF REVIEW: To outline the scientific rationale for combination therapy in multiple sclerosis and to discuss the evidence for combination treatment strategies from animal models and clinical trials of multiple sclerosis. RECENT FINDINGS: Experiments conducted in experimental autoimmune encephalomyelitis have recently shown beneficial effects of numerous combination therapies. The combination of approved and experimental drugs and two or more experimental agents may positively impact clinical disease activity, inflammation within the central nervous system, and neurorepair. Clinical trials are currently underway to establish the therapeutic efficacy and safety of various combination therapies for multiple sclerosis patients. SUMMARY: More effective therapies are needed to treat multiple sclerosis. There are good scientific rationales for the use of combination therapy in multiple sclerosis, and the pharmacologic principles for evaluating and understanding their actions are available. The evaluation of specific combination therapies in the controlled setting of clinical trials should be a priority in clinical multiple sclerosis research.

KW - Combination therapy

KW - Experimental autoimmune encephalomyelitis

KW - Immunomodulation

KW - Immunosuppression

KW - Multiple sclerosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=34248365318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248365318&partnerID=8YFLogxK

U2 - 10.1097/WCO.0b013e328122de1b

DO - 10.1097/WCO.0b013e328122de1b

M3 - Article

C2 - 17495621

AN - SCOPUS:34248365318

VL - 20

SP - 281

EP - 285

JO - Current Opinion in Neurology

JF - Current Opinion in Neurology

SN - 1350-7540

IS - 3

ER -